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Abstract
Gut microbiota has been studied in relation to human health and disease prediction for decades. Also, immune checkpoints 
(ICPs) are enthusiastically investigated for anti-tumor immunotherapy. Recent studies show potential of gut microbiome 
and gut cytokines as biomarkers for carcinogenesis and response prediction of immune checkpoint inhibitor (ICI) response. 
Evidence has revealed that intestinal microorganisms play a major role in the effectiveness of programmed cell death 1 (PD-1) 
and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade. In this review, we have focused on how microbiome 
and microbiome-generated cytokines affect immune checkpoints. We have also described the molecular mechanisms behind 
this interplay and the bacterial strains that have a potential role in immunotherapy.
Introduction
Immune checkpoints (ICPs) provide signals that regulate 
antigen recognition by the T cells, thereby preventing the 
immune system from attacking cells uncontrollably (He and 
Xu 2020). Located at the cell surface, ICPs alter the cell 
function upon binding the ligands secreted by other cells. 
Programmed cell death protein 1 (PD-1) and cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) are co-inhibitory 
ICPs; they are expressed on activated tumor-specific  CD4+ 
cells and  CD8+ T-lymphocytes, and inhibit the progression 
of the immune reaction. In the absence of ICP proteins and 
their ligands, T cells function regularly to kill tumor cells. 
However, when tumor cells express the ligands for ICP pro-
teins, they bind to the inhibitory proteins expressed on the T 
cells and inhibit the T cells from killing the tumor cells (Wei 
et al. 2018). Accordingly, the presence of an antagonist of the 
inhibitory signal known as the immune checkpoint inhibitor 
(ICI) (a corresponding antibody that inhibits the receptor 
function) enhances the antitumor immunity. The most com-
monly used inhibitors for CTLA-4 include ipilimumab and 
tremelimumab, while those for PD-1 include pembrolizumab 
and nivolumab; the inhibitors for programmed death-ligand 
1 (PD-L1), the primary ligand of PD-1, include atezoli-
mumab, avelumab, and durvalumab. The ICPs are, there-
fore, exploited by the tumor cells as an immune escape 
mechanism, suppressing the adaptive immune responses. 
Stimulated expression of the antigens expressed in the tumor 
microenvironment result in an increased expression of ICP 
proteins, which in turn decreases the effectiveness of the 
antitumor immune responses by debilitating the cytotoxic 
and cytokine-producing ability of the T cells (Darvin et al. 
2018). Thus, PD-1 and CTLA-4 are attractive targets for 
anti-cancer immunotherapy.
While various biomarkers are known to reflect the tumor 
immune microenvironment, such as tumor mutational bur-
den, mismatch-repair deficiency, and density of tumor-infil-
trating lymphocyte (TIL), recently, both cytokines and gut 
microbiome have been extensively studied owing to their 
potential to serve as biomarkers for both cancer progression 
and response prediction to ICIs (Yi et al. 2018). Cytokines, 
released in response to infection and inflammation, play a 
critical role in modulating the development and progres-
sion of malignant cells by their complex and vast network. 
Interferon (IFN), the first discovered member of the cytokine 
family, which presently forms an essential part of the innate 
immune system, evokes anti-viral defense response against 
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viral infections. Interleukins (ILs), another important fam-
ily of cytokines, are responsible for various functions of the 
immune cells, including activation, proliferation, motility, 
and differentiation. Hence, they exhibit both pro- and anti-
inflammatory properties (Zhang and An 2007). While the 
immunological functions of most ILs are known, many are 
yet to be unveiled. A few ILs have biphasic effects and some 
even have differences in their function depending upon the 
type of the tumor cell present. In practice, cytokines have 
been implemented as biomarkers to observe cancer cell pro-
gression in various cancer patients.
Gut microbiota has a vital role in modulating the immune 
system responses. Furthermore, it has been reported that the 
gut microbiome essentially governs the efficacy of PD-L1. In 
this review article, various studies revealing the effect of the 
microbiome on the efficacy of PD-1 and CTLA-4 blockade 
have been reviewed. Negative impact of dysbiosis due to 
antibiotics on the efficacy of PD-1 and CTLA-4 blockade 
was also affirmed. Fecal microbiome transplant (FMT) from 
patients responsive to the ICI treatment resulted in improved 
efficacy of ICP blockade. These studies identified several 
bacterial genera imparting benefits to ICI treatment. Immune 
mechanisms that altered the efficacy of the ICP blockade 
treatment involved cytokines. The related studies have been 
summarized in Table 1.
Main text
Although immunotherapy is a long-used practice, it has 
recently achieved exceptional success against distinct hema-
tological and solid metastatic malignancies (Waldmann 
2003). It has been reported that the ICIs disrupt the interac-
tion between the ligands and the T cell inhibitory receptors, 
inducing T lymphocyte-mediated immune responses (Par-
doll 2015). PD-1 blockade with its corresponding mono-
clonal antibodies (mAbs) is remarkably effective against 
advanced melanoma, non-small cell lung cancer (NSCLC), 
and renal cell carcinoma (RCC) (Routy et al. 2018).
PD‑1 antibody immunotherapy and the effect 
of FMT on PD‑1 antibody efficacy
The study by Routy et al. ushered in a new perspective by 
connecting the field of microbiome and immunotherapy 
targeting PD-L1 (Routy et al. 2018). The prospect that pri-
mary resistance to PD-1 blockade may be affected by the 
microbial imbalance associated with antibiotic or malignant 
disease in tumor-bearing mice and cancer patients was inves-
tigated. The authors concluded that the aberrant composition 
of the gut microbiome can result in primary resistance to 
ICIs. The impact of antibiotics (ATBs) on cancer patients, 
specifically those having advanced NSCLC, RCC, or 
urothelial carcinoma, after they received PD-1/PD-L1 mAb 
treatments was studied. In the absence of ATBs, the tumor 
growth was significantly reduced when injected with PD-1 
mAbs. However, mAbs were essentially ineffective when the 
mice (with RET melanoma and MCA-205 sarcoma) were 
previously treated with ATB. Hence, antibiotic consump-
tion was correlated to negative response to PD-1 blockade. 
Based on the response evaluation criteria in solid tumors 
(RECIST) version 1.1 (Eisenhauer et al. 2009), patients 
who received PD-1/PD-L1 treatment were segregated into 
two groups: responders (R) and non-responders (NR). FMT 
from the stool samples of these patients to ATB-treated mice 
revealed that the stool samples from the R patients induced 
sensitivity, while those from NR patients induced resistance 
to PD-1 blockade, which is commensurate with efficiency in 
ATB-treated or germ-free mice. Two weeks after the inocu-
lation with fecal samples and MCA-205 tumor cells, the 
ATB-treated mice were subjected to treatment with PD-1 
mAbs. The mice that received FMT from R patients showed 
slower tumor growth than those that received FMT from NR 
patients. Between the two groups, the R group was enriched 
with several key bacterial genera and strains compared to the 
other. Akkermansia muciniphila, the most prominent com-
mensal bacterium associated with positive clinical outcome, 
was found in both NSCLC and RCC patients. Enterococ-
cus hirae 13144 (E. hirae) was also observed repeatedly in 
R-NSCLC patients. A combination of A. muciniphila and 
E. hirae led to the accumulation of central memory  CD4+ 
T cells expressing chemokine receptors CCR9 (associated 
with small intestine) and CXCR3 (associated with T helper 
1 (Th1) immune response). Increased recruitment of these 
 CD4+ T cells is dependent on IL-12 secretion induced by A. 
muciniphila and E. hirae.
CTLA‑4 blockade immunotherapy
A similar study by Vetizou et al. revealed an IL-12-depend-
ent Th1 immune response induced by Bacteroides fragilis, 
which resulted in an increased response to CTLA-4 blockade 
(Vétizou et al. 2015). The authors found that the CTLA-4 
blockade-induced immune-stimulatory effects were depend-
ent on the microbiome, which in turn was regulated by the 
mobilization of intestinal lamina propria  CD11b+ dendritic 
cells (DC) and IL-12-associated Th1 immune response. 
Germ-free mice and mice treated with a combination of 
antibiotics, including ampicillin, colistin, and streptomycin 
(ACS), were re-colonized with bacterial species associated 
with CTLA-4 antibody-treated intestinal mucosa. In both 
groups of mice, reduced activation of the  CD4+ T cells and 
TILs in Ret melanoma and the MC38 colon cancer models 
indicated significantly reduced efficacy of CTLA-4 antibody. 
The  CD4+ T cells that were harvested from the spleens of 
CTLA-4 antibody-treated mice, or from the blood of the 
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patients with metastatic melanoma (MM) or NSCLC after 
treatment with ipilimumab, demonstrated recovery of the 
Th1 phenotype. B. fragilis was observed to partially restore 
the efficacy of CTLA-4 antibody that was reduced due to 
the lack of gut microbiota. Abundance of B. fragilis was 
associated with reduced size of the tumor in the CTLA-4 
blockade-treated mice. Hence, the microbiota composition 
influenced the efficacy of CTLA-4 blockade (B. fragilis and/
or B. thetaiotaomicron and Burkholderiales).
The effect of specific bacterial strains, cytokines 
and immune cells on immunomodulation
Garris et al. in their study reinforced the significant role of 
IL-12 in antitumor responses (Garris et al. 2018). The study 
findings revealed that the activation of antitumor T cells by 
anti-PD-1 is indirect, as it requires a crosstalk between the T 
cells and DCs. The crosstalk is, however, dependent on IFN 
gamma (IFN-ɣ) and IL-12. Anti-PD-1 mAbs antagonize the 
PD-1 inhibitory pathway in T cells and, thereby, heighten 
the activation of  CD8+ T cells. In turn, the DCs sense the 
IFN-ɣ released from the mAb-activated T cells, instead of 
binding directly to the drug. DCs produce IL-12, which then 
stimulates the antitumor T cell immunity and sensitizes the 
tumors to anti-PD-1 treatment. Moreover, activation of the 
non-canonical nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-kB) transcription factor pathway 
augments the DCs that produce IL-12. Thus, NF-kB was 
identified as a potential therapeutic target for enhancing the 
checkpoint blockade response.
Xu et al. established the gut microbial genome and vari-
ous plasma metabolites associated with PD-1 antibody 
immunotherapy in CT26 tumor-bearing mice. The 16S ribo-
somal RNA (rRNA) gene sequencing, metagenomic shotgun 
sequencing, and non-targeted metabolomic analyses revealed 
that antibiotic treatment altered the taxonomic composition 
of the gut (Xu et al. 2020). An abnormal gut microbiome 
lowered the efficacy of PD-1 antibody immunotherapy. The 
relative therapeutic efficacy of PD-1 antibody treatment in 
combination with different antibiotics varied among the 
experimental groups: control group (good-response), van-
comycin-treated (Vanc) group (medium-response), colistin-
treated (Coli) group (poor-response), and ACS-treated group 
mice (no-response). Prevotella sp. CAG: 485 and A. mucin-
iphila were related to positive therapeutic immunotherapy 
efficacy. On the contrary, Bacteroides sp. and Bacteroides 
sp. CAG: 927 were associated with negative therapeutic effi-
cacy. Similar to the observations by Routy et al. (2018), this 
study also revealed enhanced immunotherapeutic efficiency 
on enriching the intestine with Akkermansia sp. The better 
efficacy of PD-1 antibody was linked to the glycerophospho-
lipid metabolic pathway, as changes in the gut microbiome 
altered the level of glycerophospholipid metabolism. Xu and 
his colleagues detected that while there was no change in the 
number of  CD4+ and  CD8+ T cells, the cell IFN-ɣ and IL-2 
concentrations in the antibiotic-treated groups were signifi-
cantly reduced compared to that in the control group. Thus, 
it was suggested that metabolism may affect the expression 
of immune-related cytokines, IFN-ɣ and IL-2, in the tumor 
microenvironment, which then alters the therapeutic effect of 
PD-1 antibody. In addition, the metagenomic pathway func-
tion prediction demonstrated IL-17 secretion to be linked 
with negative immunotherapeutic efficacy.
Sivan et al. compared the effects of anti-PD-1/PD-L1 
mAbs by observing the subcutaneous B16.SIY melanoma 
growth in genetically similar C57BL/6 mice obtained 
from Jackson Laboratory (JAX) and Taconic Farms (TAC) 
(Sivan et al. 2015), which harbored a disparate commen-
sal microbiota. Aggressive tumor growth observed in TAC 
mice resulted from an immune-mediated response. Both 
the accumulation of intratumoral  CD8+ T cells and the 
responses of tumor-specific T cells were lower in TAC mice 
than that in JAX mice. Transfer of JAX fecal material into 
TAC mice alone was sufficient to reduce the tumor growth 
rate and increase the infiltration of the  CD8+ T cells. When 
the JAX fecal material was combined with PD-L1, tumor 
control and tumor antigen-specific T cell responses were 
enhanced. This indicates that the composition of the com-
mensal microbiome affects the antitumor immunity and the 
efficacy of anti-PD-L1 mAb. The only genus-level taxon that 
significantly correlated with the accumulation of activated 
antigen-specific T cells was Bifidobacterium. The strongest 
association was reported with antitumor T cell response, and 
it significantly increased with the transplant of JAX fecal 
material into TAC. The positive effect in JAX mice could be 
attributed to Bifidobacterium. When the mice were treated 
with Bifidobacterium, tumor control was notably enhanced. 
The mechanism of this therapeutic effect is rather indirect, 
mediated by the host antitumor T cell responses, as Bifido-
bacterium treatment led to extensive induction of tumor-
specific T cells. However, Bifidobacterium had no effect in 
CD8-depleted mice. TAC mice inoculated with B16 parental 
tumor cells or MB49 bladder cancer cells, when subjected 
to treatment with Bifidobacterium displayed delayed tumor 
growth. Hence, administration of a cocktail of Bifidobacte-
rium sp. in TAC mice containing melanoma was identified 
as a positive promoter of antitumor response. Further, in 
combination with ICI, tumor growth significantly decreased. 
In both JAX and Bifidobacterium-treated TAC mice, an 
augmented proportion of major histocompatibility com-
plex (MHC) Class  IIhi DCs and IFN-ɣ were reported in the 
tumors.
Matson et al. examined baseline stool samples from meta-
static melanoma patients to evaluate the association between 
commensal bacterial composition and clinical efficiency of 
PD-1 blockade immunotherapy (Matson et al. 2018). Similar 
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to the study by Routy et al. (2018), the patients were catego-
rized into R and NR groups based on the RECIST 1.1 ver-
sion. Three weeks after inoculation with B16.SIY melanoma 
cells, the R microbiota-reconstituted mice exhibited a sig-
nificant increase in SIY-specific  CD8+ T cells (thereby aug-
menting priming of tumor antigen-specific  CD8+ T cells), 
but no change was observed in  FoxP3+CD4+ regulatory T 
cells. IFN-ɣ enzyme-linked immunosorbent spot of ex vivo 
SIY-stimulated splenocytes also exhibited an increased fre-
quency of activated T cells. While anti-PD-L1 efficacy was 
enhanced in mice colonized with R microbiota, mice colo-
nized with NR microbiota exhibited completely ineffective 
anti-PD-L1. Slower baseline tumor growth in two of the 
three R-derived mouse cohorts was congruent with the find-
ings of the study by Sivan et al. (2015) that reported FMT 
from R alone to be insufficient in inducing slower tumor 
growth. An integration of three methods (16S rRNA gene 
sequencing, metagenomic shotgun sequencing, and quanti-
tative polymerase chain reaction (qPCR) for selected bac-
teria) revealed ten species that were differentially enriched 
in R versus NR groups. Eight bacterial species abundant 
in the R group, included Enterococcus faecium, Collin-
sella aerofaciens, Bifidobacterium adolescentis, Klebsiella 
pneumoniae, Veillonella parvula, Parabacteroides merdae, 
Lactobacillus sp., and Bifidobacterium longum. Ruminococ-
cus obeum and Roseburia intestinalis were abundant in the 
NR group. This again complies with the study by Sivan and 
colleagues, who reported Bifidobacteriaceae family mem-
bers to be associated with better immune-mediated tumor 
control and positive efficacy of the anti-PD-L1 therapy in 
mice. Monocolonization with the R group-enriched spe-
cies resulted in decreased frequency of the colonic regu-
latory T cells, increased frequency of Batf3-lineage DCs, 
and enhanced Th1 response. Thus, the data suggests that the 
composition of the commensal microbiota plays a signifi-
cant role in determining the therapeutic efficacy of anti-PD-1 
monoclonal antibody and, hence, can be used as a biomarker 
for clinical response.
Daillere et al. announced two bacterial species, E. hirae 
and Barnesiella intestinihominis, that play an important role 
in determining the antitumoral efficacy of cyclophosphamide 
(CTX), an anti-cancer immunomodulatory agent (Daillère 
et al. 2016). E. hirae, a gram-positive bacteria residing 
in the small intestine, was found to selectively restore the 
CTX-mediated antitumor effects in ATB-treated mice and 
improved the cognate anticancer immune response. E. hirae 
specifically induced the systemic effector pathogenic Th17 
(pTh17) cell responses related to MHC class I-restricted 
cytotoxic T cells (CTL) and significantly decreased the 
level of  Foxp3+CD25+CD4+TILs resulting in increased 
intratumoral CTL/T regulatory (Treg) cell ratio. The gram-
negative B. intestinihominis, residing in the colon, enhanced 
the systemic polyfunctional  CD4+ Tc1 and  CD8+ Th1 cell 
responses by augmenting the proportions of intratumoral 
IFN-ɣ-producing ɣdTILs while decreasing IL-17-producing 
ɣdTILs. In the spleen, E. hirae and B. intestinihominis, rep-
resenting oncomicrobiotics (OMBs), facilitated the accumu-
lation of effector  CD8+ T cells by inverting the CD4/CD8 T 
cell ratio. Repetitive gavages of either OMB ameliorated the 
CTX activity against MCA-205 fibro-sarcoma. Gavages with 
B. intestinihominis were also efficacious against Ret mela-
noma. Daillere and colleagues found that IFN-ɣ neutraliza-
tion with unaltered IL-17 or  CD8+ T cell depletion critically 
debilitated the anticancer efficacy of the two commensals 
against MCA-205. Therefore, these OMBs exhibit the effect 
of an adjuvant on the tumoral immune responses, enhancing 
the efficacy of CTX. The authors also discovered that the 
immune-dependent anti-sarcoma effects of CTX were con-
siderably enhanced in nucleotide oligomerization domain 
2-deleted (Nod2−/−) mice. CTX-treated sarcoma growing in 
Nod2−/− mice showed lower number of Treg cells and higher 
number of IFN-ɣ-producing ɣdTILs compared to sarcoma 
growing in a wild type environment. Hence, NOD2 receptors 
were suggested to function as “gut immune checkpoints” 
that limited the immunogenicity of E. hirae and B. intestini-
hominis. Therefore, NOD2 hinders the accumulation of the 
two OMBS and restricts their proapoptotic effects on the epi-
thelial cells. The study also concluded the immune response 
of memory Th1 toward E. hirae or B. intestinihominis to 
govern the progression-free survival in cancer patients.
Gopalakrishnan et  al. investigated the oral and gut 
microbiome of melanoma patients who received anti-PD-1 
immunotherapy based on a previous research finding that 
reported gut microbiome to modulate the tumor response 
to ICI treatment (Gopalakrishnan et al. 2018). They ana-
lyzed the patient’s fecal microbiome samples and assessed 
the relative abundance of bacteria in the R and NR groups. 
The bacterial population was significantly different between 
the two groups. The R group exhibited substantially higher 
alpha diversity and higher frequency of bacteria belong-
ing to the Ruminococcaceae family (p < 0.01) than the NR 
group. This favorable gut microbiome exhibited improved 
antitumor immunity in R patients and fecal transplanted 
germ-free mice. High abundance of Faecalibacterium sp. 
in the R group heightened the antigen presentation and T cell 
function in the tumor microenvironment, thereby, enhanc-
ing the antitumor immune responses. On the other hand, 
high relative abundance of Bacteroidales was associated 
with decreased antitumor immune responses owing to the 
diminished antigen presentation capacity. While increased 
activation of  CD8+ T cells was observed in R-FMT mice, 
the spleen of NR-FMT mice exhibited increased levels of 
regulatory  CD4+FoxP3+ T cells and CD4 IL-17 T cells. 
This suggests that FMT from NR resulted in impaired host 
immune responses. The study emphasized on the therapeu-
tic potential of regulating microbial composition in patients 
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undergoing ICI therapy. While Gopalakrishnan et  al., 
Routy et al., and Matson et al. studied the link between gut 
microbiome and efficacy of anti-PD-1 mAb in solid can-
cers (Gopalakrishnan et al. 2018; Matson et al. 2018; Routy 
et al. 2018), Matson et al.’s study was an exception owing to 
the different method used to identify the R and NR patients 
(Matson et al. 2018).
In a similar study, Tanoue et al. studied 11 bacterial 
strains that were positively associated with the frequency 
of IFN-ɣ-producing CD8 T cells. These bacterial strains, 
isolated from healthy human donor feces, were mixed inocu-
lated into germ-free mice (GF+11-mix mice) (Tanoue et al. 
2019). A substantial increase in IFN-ɣ+ CD8 T cells was 
found in diverse genetic backgrounds, with relative enrich-
ment for the T cell receptor (TCR) Vβ6+ and Vβ8+ subsets. 
GF+11-mix mice also exhibited induction of CD4 T cells, 
increasing the frequencies of colonic Th17 and Th1 cells as 
well. Among these 11 strains, 7 were Bacteroidales, which 
when mixed and inoculated into germ-free mice (7-mix) 
were incapable of inducing IFN-ɣ + CD8 T cells. The 
mix of the other 4 strains, which were non-Bacteroidales, 
although exhibited a better induction capacity, but still was 
not sufficient to yield the complete inductive effect of the 
11-mix. Hence, it was suggested that the 11 strains, includ-
ing the 7 Bacteroidales as supporting strains and the 4 non-
Bacteroidales as effector elements, formed a consortium. 
The upregulation of chemokines CXCl9, CXCl10, and IFN-
inducible genes in the colonic epithelial cells by the colo-
nization of the 11-mix suggested that the recruitment and 
accumulation of IFN-ɣ + CD8 T cells can be promoted by 
active colonization near epithelial cells, establishing an IFN-
ɣ-mediated feed-forward loop. Subcutaneous engraftment of 
GF+11-mix mice with MC38 adenocarcinoma cells showed 
significantly improved anti-PD-1 treatment efficacy, com-
pared to that in germ-free mice and in mice with strains that 
do not induce IFN-γ+ CD8 T cells. This therapeutic effect 
was a result of increased IFN-γ+ CD8 TILs, as the deple-
tion of CD8 T cell by antibody notably reduced the efficacy. 
Interestingly, the colonization of 11-mix even suppressed the 
tumor growth without anti-PD-1 treatment. Altogether, this 
data demonstrates that the 11 strains with non-inflammatory 
immunomodulatory activity enhance both ICI-mediated and 
spontaneous anti-tumor immunity in a CD8 T cell-dependent 
manner. Evaluating the abundance of the 11 strains using 
metagenomic datasets, it was observed that majority of 
the strains were rare and low-abundance components of 
the human microbiota. The low-abundance trend was also 
established in both R and NR with melanoma receiving ICI 
treatment in the studies by Gopalakrishnan et al. (2018), 
Routy et al. (2018) and Matson et al. (2018).
Likewise, Pushalkar et  al. established a specific gut 
microbiome that is linked to the progressive pancreatic onco-
genesis in mice (Pushalkar et al. 2018). Analyzing the gut 
microbiome using 16S rRNA fluorescence in-situ hybridiza-
tion (FISH) and qPCR, it was observed that both the mouse 
and human pancreatic ductal adenocarcinoma (PDA) exhibit 
significantly greater bacterial abundance compared to the 
normal pancreas. The most abundant of the 13 phyla that 
were detected in the human PDA were Proteobacteria, Bac-
teroidetes, and Firmicutes. The PDA-associated microbiome 
differentially activated selective Toll-like receptors (TLR) in 
order to create a tolerogenic immune program. The micro-
biome was observed to render suppressive effects on the 
T-cell activation when polarized on macrophages. However, 
in the absence of TLR signaling, this effect was attenuated. 
Bifidobacterium pseudolongum, differentially abundant in 
both gut and tumor, was also reported to accelerate oncogen-
esis in a TLR-dependent manner. Further, the macrophages 
polarized by cell-free extracts of B. pseudolongum upregu-
lated the tolerogenic cytokine IL-10. Ablation of the gut 
bacteria by oral administration of antibiotics resulted in an 
increased activation of Th1 differentiation of both of  CD4+ 
and  CD8+ T cells and decreased immune-suppressive cells. 
Thus, the ablation was associated with decrease in immune-
suppressive  CD206+ M2-like tumor-associated macrophages 
(TAM), an adjuvant to increase M1-like TAMs, which 
express MHC II, CD86, tumor necrosis factor alpha (TNF- 
α), IL-12, and IL-6. High expression of T-BET, TNF-α, and 
IFN-ɣ indicated an enhanced cytotoxic phenotype of  CD8+ 
T cells. The authors, thus, suggested bacterial ablation to 
create a synergistic efficacy with PD-1-directed therapies. 
Bacterial transfer from PDA-bearing hosts reversed the pro-
tective effect of microbial ablation against PDA. However, 
the reversion was not evident in a transfer from control-host; 
thus, emphasizing on the pro-tumorigenic effect of PDA-
associated microbiome.
Metabolites as a mechanism of modulating host 
cytokines and anticancer therapeutics
While the specific functions and molecular mechanism of 
the gut microbiome are yet largely unidentified, Lee et al. 
explored a few of the strain-specific mechanisms of how the 
microbiome affects cancer development and the efficacy of 
anti-cancer therapy (Lee et al. 2021). Lee et al. found that 
the increase in anticancer immunity due to B. bifidum strain-
specific enhancement of anticancer immunity is a result of 
IFN-γ signaling. In addition, the B. bifidum-induced IFN-γ 
production was enhanced by the increase in serum metabo-
lites and peptidoglycan biosynthesis.
Lee et al. collected intestinal tissues from tumor mice 
treated with anti-PD-1 plus synergistic B. bifidum strains 
(B. bif_K57) or non-synergistic strains (B. bif_B06). By 
performing RNA sequencing intestinal tissues, they were 
able to observe a notably higher number of genes associ-
ated with Gene Ontology terms “lymphocyte activation”, 
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“interferon-gamma production” and “positive regulation of 
interferon-gamma production” in mice treated with anti-
PD-1 with B. bif_K57 compared to those treated with B. 
bif_B06. Serum metabolic profiling showed that the concen-
trations of l-tryptophan, uric acid, and N-acetyl zonisamide 
were higher in mice treated with anti-PD-1 plus B. bif_K57 
compared to mice treated with anti-PD-1 plus B. bif_B06. 
It was also found that in vitro, the addition of l-tryptophan 
increased IFN-γ production from activated CD8+ T cells. 
Mice treated with anti-PD-1 plus B. bif_B57 exhibited the 
lowest serum lipid levels, followed by mice treated with anti-
PD-1 plus B. bif_B06 and then anti-PD-1. This, in line with 
a previous study that demonstrated that lipid challenge leads 
to the decrease in T cell secretion of IFN- γ (Guerrero-Ros 
et al. 2020), shows that lowering the lipid level is an exam-
ple of a mechanism by which the microbiome modulates 
cytokines.
Lee et al. also discovered that the peptidoglycan levels 
were significantly higher in B. bif_K57 compared with B. 
bif_B06. MurE and GlmM, which are the genes associated 
with the peptidoglycan biosynthetic process, were expressed 
more strongly in anti-PD-1 plus B. bif_K57-treated mice 
stools compared to anti-PD-1 plus B. bif_B06-treated mice. 
In patients with NSCLC, the stool samples of patients con-
taining the B. bifidum exhibited enriched peptidoglycan 
biosynthesis pathway, compared to bifidum-free patients, 
demonstrating the effect of peptidoglycans on immune 
modulation.
Conclusion
The findings of the different studies discussed in this review 
highlighted a strong correlation between the gut microbiota 
and immune system. The significant role of the gut micro-
biome in regulating the antitumor activity of ICIs was also 
elucidated. Notably, species belonging to the genera Akker-
mansia (Routy et al. 2018; Xu et al. 2020), Enterococcus 
(Daillère et al. 2016; Matson et al. 2018; Routy et al. 2018), 
Bifidobacterium (Matson et al. 2018; Pushalkar et al. 2018; 
Sivan et al. 2015) and Ruminococcaceae (Gopalakrishnan 
et al. 2018; Tanoue et al. 2019) were found to improve 
the immune responses and increase the efficacy of PD-1 
blockade therapy. Interestingly, the genus Bacteroides has 
been found to induce biphasic effects. While some strains 
of Bacteroides increase the response to CTLA-4 blockade 
(Vétizou et al. 2015), other strains of this genus are asso-
ciated with negative therapeutic efficacy of PD-1 antibody 
immunotherapy (Xu et al. 2020). Gut microbial changes 
induce changes in the expression of cytokines and immune 
cells, resulting in differential therapeutic responses. Par-
ticular cytokines, IFN-ɣ (Daillère et al. 2016; Garris et al. 
2018; Matson et al. 2018; Routy et al. 2018; Tanoue et al. 
2019; Xu et al. 2020), IL-12 (Garris et al. 2018; Routy et al. 
2018; Vétizou et al. 2015), and IL-17 (Daillère et al. 2016; 
Gopalakrishnan et al. 2018), have been reported as the key 
cytokines that are used by certain bacterial strains to affect 
the immunomodulation. Additionally, immune cells such as 
the  CD8+ T cells (Matson et al. 2018; Pushalkar et al. 2018; 
Sivan et al. 2015; Tanoue et al. 2019) and  CD4+ T cells 
(Routy et al. 2018; Gopalakrishnan et al. 2018; Daillère et al. 
2016; Pushalkar et al. 2018) have also been identified to be 
responsible for the responsiveness to ICP blockade therapy. 
The mechanism behind the strain-specific enhancement of 
anticancer immunomodulation was studied by Lee et al., in 
which they found that the IFN-γ signaling was the key to the 
B. bifidum strain-specific anticancer immunity (Lee et al. 
2021). More importantly, they discovered that the increase 
in serum l-tryptophan, along with other serum metabolites, 
and peptidoglycan biosynthesis augmented the B. bifidum-
induced IFN-γ production.
While some cytokines reveal the possible mechanism by 
which specific bacterial strains confer increased efficacy of 
ICI therapy, future studies are warranted to elucidate the 
detailed molecular mechanism of the mutual interaction. In 
addition, a more comprehensive analysis of the microbial 
composition associated with anticancer response will be 
necessary to better understand the link between the micro-
biome and their immunomodulatory effects. The isolated 
strains carry significant biotherapeutic potentials: they can 
be utilized as biomarkers to predict the efficacy of ICI and 
can also be applied to treat cancer and other related diseases.
Bacterial components are well-known pathogen-asso-
ciated molecular patterns (PAMPs) that induce the innate 
immune system via the TLRs. However, antitumor immunity 
is usually exerted by the adaptive immune system, such as 
CD8 cytotoxic T cells specific for cancer peptides. Thus, it is 
important to clarify how the PAMPs activate cancer-specific 
adaptive immunity. Furthermore, while certain bacterial spe-
cies enhance the efficacy of ICIs, some repress its efficacy, 
implying that the antitumor activity of the bacteria may not 
stem from the simple activation of the innate immune sys-
tem by common PAMPs, such as lipopolysaccharide (LPS). 
More detailed understanding on how gut microbiota controls 
the systemic immune system is essential for better under-
standing and development of efficient therapeutics against 
cancers that lack efficient treatment strategies.
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